Targeting CD133 reverses drugresistance via the AKTNFBMDR1 pathway in colorectal cancer

Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer

23:26 EDT 15 Mar 2020 | Nature Publishing

More From BioPortfolio on "Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer"